New Stock News | Norin Bio's Hong Kong IPO prospectus has expired

Nanjing Nuoling Biotechnology Co., Ltd. (referred to as: Nuoling Biotechnology) submitted its Hong Kong stock prospectus on February 13, 2026, which will expire six months later on August 13, 2026, with Jianyin International acting as the sole sponsor at the time of submission. According to the previously disclosed prospectus, Nuoling Biotechnology focuses on the research and commercialization of inhaled nitric oxide (iNO) therapy. Based on data from Frost & Sullivan, Nuoling Biotechnology is one of the few companies globally capable of achieving autonomous control over the entire nitric oxide (NO) technology chain, and the only company worldwide with a comprehensive product line covering both NO treatment and diagnostic applications. As of the last practical date, Nuoling Biotechnology has five approved products and four candidates under research, covering critical care, ward, outpatient, and home disease management in the cardiopulmonary treatment field, including three major product lines: (i) iNO therapy; (ii) cardiopulmonary circulation support; and (iii) exhaled breath diagnostics.